Ocugen, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
OCGN Nasdaq 2834 www.ocugen.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Ocugen, Inc.

Ocugen's Q3 Earnings Match Estimates, Revenues Beat, Stock Rises - Nov 5th, 2026 5:40 am
Ocugen Inc (OCGN) Q3 2026 Earnings Call Highlights: Three Gene Therapy Programs Reach Phase 3 ... - Nov 4th, 2026 2:11 pm
Ocugen Q3 Earnings Call Highlights - Nov 4th, 2026 12:14 pm
Ocugen, Inc. Q3 2026 Earnings Call Summary - Nov 4th, 2026 11:34 am
Ocugen (OCGN) Q3 2026 Earnings Call Transcript - Nov 4th, 2026 10:30 am
Ocugen (OCGN) Reports Q3 Loss, Tops Revenue Estimates - Nov 4th, 2026 5:55 am
Ocugen: Q3 Earnings Snapshot - Nov 4th, 2026 5:14 am
Ocugen Provides Business Update with Third Quarter 2026 Financial Results - Nov 4th, 2026 5:00 am
Ocugen to Participate in Upcoming November Investor and Industry Conferences - Oct 29th, 2026 5:02 am
Ocugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4 - Oct 22nd, 2026 5:00 am
Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa - Oct 14th, 2026 4:30 am
Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate - Oct 6th, 2026 5:02 am
Ocugen to Participate in Upcoming Scientific Conferences - Sep 30th, 2026 5:02 am
Retinitis Pigmentosa Market Outlook to Strengthen During the Forecast Period (2026-2036) with Growing Focus on Disease-Modifying Therapies | DelveInsight - Sep 29th, 2026 8:31 am
Ocugen to Participate in Upcoming October Investor and Industry Conferences - Sep 29th, 2026 5:02 am
Sector Update: Healthcare Stocks Edge Higher in Afternoon Trading - Sep 25th, 2026 11:57 am
Ocugen Eyes Global Access For Gene Therapy After Bahamas Boost — First Eye Disorder Patient Could Be Treated Within 90 Days - Sep 25th, 2026 6:51 am
Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa - Sep 25th, 2026 5:02 am
Ocugen Targets Three Gene Therapy BLA Filings as Retinal Pipeline Advances - Sep 15th, 2026 10:02 pm
OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy - Sep 2nd, 2026 8:52 am